SCHEMBL7590184

SCHEMBL7590184

N#Cc1c(Cl)c(-c2cccnc2)n2c1C(Cl)=C(Cl)CC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 4/20 0.46
CYP11B1 P15538 2/20 0.46
MAOA P21397 1/20 0.46
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 6/20 0.40
HSD17B10 Q99714 4/20 0.40
HTT P42858 3/20 0.40
TSHR P16473 2/20 0.40
ALDH1A1 P00352 4/20 0.38
MAPK1 P28482 2/20 0.38
MEN1 O00255 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ADORA2A P29274 3/20 0.38
ADORA1 P30542 2/20 0.38
CYP1A2 P05177 1/20 0.38
GAA P10253 2/20 0.37
APOBEC3G Q9HC16 1/20 0.37
RXFP1 Q9HBX9 2/20 0.37
DYRK1A Q13627 1/20 0.37
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7585391 0.99 CYP11B2 (0.45) CYP11B2CYP11B1MAOAKMT2AKDM4E
SCHEMBL2157283 0.81 CYP11B2 (0.44) CYP11B2CYP11B1MAOAKMT2AKDM4E
SCHEMBL7592502 0.79 CYP11B2 (0.42) CYP11B2CYP11B1MAOAKMT2AKDM4E
SCHEMBL2158205 0.78 KDM4E (0.45) CYP11B2CYP11B1MAOAKMT2AKDM4E
SCHEMBL7964663 0.77 CYP11B2 (0.41) CYP11B2CYP11B1MAOAKMT2AKDM4E
SCHEMBL2157245 0.76 CYP11B2 (0.42) CYP11B2CYP11B1MAOAKMT2AKDM4E
SCHEMBL7952767 0.75 CYP11B2 (0.44) CYP11B2CYP11B1MAOAKMT2AKDM4E
SCHEMBL2158233 0.74 CYP11B2 (0.42) CYP11B2CYP11B1MAOAKMT2AKDM4E
SCHEMBL7845092 0.73 CYP11B2 (0.41) CYP11B2CYP11B1MAOAALDH1A1CYP1A2
SCHEMBL2158211 0.71 KMT2A (0.40) CYP11B2CYP11B1MAOAKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them MIGNANI SERGE (FR) 2002-01-17 US disclosed
EP-1086100-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2001-03-28 EP disclosed
WO-1999064419-A1 PYRROLE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA S.A. (FR) 1999-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006380-A1 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them TNF, IL2, ZC3HAV1 CYP11B2 139/4885CYP11B1 130/4885MAOA 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.